Advanced Search
Contact | Corporate | Help

BIBF 1120 as Second Line Treatment for Small Cell Lung Cancer

Sponsors:
  • Ji-youn Han
  • National Cancer Center, Korea
Phases:
  • Phase II
IndicationsAcronym:
  • Small Cell Lung Cancer
  • Small Cell Lung Cancer Recurrent
Age Groups:
  • Adult
  • Senior
Gender:
Both
Names:
  • Drug: BIBF 1120
Enrollment:
51

Additional information about NCT01441297.


SourceSolution © 2008-2012